Form 8-K Revance Therapeutics, For: Nov 08
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% on concerns over AI buildout costs, Fed rate outlook
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil prices fall as investors focus on Hormuz flows after peace talks
- SpaceX slides, tech stocks dip — what’s moving markets
- Deutsche Bank cuts gold outlook as Fed repricing weighs on prices
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Revance Therapeutics (RVNC) Misses Q3 EPS by 92c; Offers Guidance
November 8, 2023 4:50 PM ESTRevance Therapeutics (NASDAQ: RVNC) reported Q3 EPS of ($1.63), $0.92 worse than the analyst estimate of ($0.71). Revenue for the quarter came in at $56.8 million versus the consensus estimate of $59.29 million.
In September 2023, Revance revised its 2023 GAAP and Non-GAAP operating expense guidance to reflect... More
